Yantai Zhenghai Biotechnology Co., Ltd. (SHE:300653)
14.29
+0.24 (1.71%)
Nov 6, 2026, 9:25 AM CST
SHE:300653 Revenue
Yantai Zhenghai Biotechnology had revenue of 71.39M CNY in the quarter ending September 30, 2026, a decrease of -18.76%. This brings the company's total for the last twelve months to 319.58M, down -8.06% year-over-year. In the year 2025, Yantai Zhenghai Biotechnology had annual revenue of 364.14M with 0.25% growth. That makes Yantai Zhenghai Biotechnology the 28,294th largest company in the world by revenue and 4,843rd in China.
Revenue (ttm)
319.58M
Revenue Growth
-8.06%
P/S Ratio
7.94
Revenue / Employee
827.94K
Employees
386
Market Cap
2.54B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 364.14M | 913.16K | 0.25% |
| Dec 31, 2024 | 363.23M | -50.43M | -12.19% |
| Dec 31, 2023 | 413.65M | -19.57M | -4.52% |
| Jan 1, 2023 | 433.22M | 33.05M | 8.26% |
| Dec 31, 2021 | 400.18M | 106.89M | 36.45% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Shanghai Universal Biotech | 1.22B |
| Beijing Kawin Technology Share-Holding | 1.21B |
| Zhejiang East Asia Pharmaceutical | 952.80M |
| Guangdong VTR Bio-Tech | 827.06M |
| Landfar Bio-medicine | 748.74M |
| Hubei Goto Biopharm Group | 665.71M |
| Zhejiang Shouxiangu Pharmaceutical | 590.94M |
| Lifecome Biochemistry | 453.12M |